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Abstract
Spontaneously hypertensive rat (SHR) is a suitable model for studies of the complications of hypertension. It is known that
activation of poly(ADP-ribose) polymerase enzyme (PARP) plays an important role in the development of postinfarction as
well as long-term hypertension induced heart failure. In this study, we examined whether PARP-inhibitor (L-2286) treatment
could prevent the development of hypertensive cardiopathy in SHRs. 6-week-old SHR animals were treated with L-2286
(SHR-L group) or placebo (SHR-C group) for 24 weeks. Wistar-Kyoto rats were used as aged-matched, normotensive controls
(WKY group). Echocardiography was performed, brain-derived natriuretic peptide (BNP) activity and blood pressure were
determined at the end of the study. We detected the extent of fibrotic areas. The amount of heat-shock proteins (Hsps) and
the phosphorylation state of Akt-1Ser473, glycogen synthase kinase (GSK)-3bSer9, forkhead transcription factor (FKHR)Ser256,
mitogen activated protein kinases (MAPKs), and protein kinase C (PKC) isoenzymes were monitored. The elevated blood
pressure in SHRs was not influenced by PARP-inhibitor treatment. Systolic left ventricular function and BNP activity did not
differ among the three groups. L-2286 treatment decreased the marked left ventricular (LV) hypertrophy which was
developed in SHRs. Interstitial collagen deposition was also decreased by L-2286 treatment. The phosphorylation of
extracellular signal-regulated kinase (ERK)1/2Thr183-Tyr185, Akt-1Ser473, GSK-3bSer9, FKHRSer256, and PKC eSer729 and the level of
Hsp90 were increased, while the activity of PKC a/bIIThr638/641, f/l410/403 were mitigated by L-2286 administration. We could
detect signs of LV hypertrophy without congestive heart failure in SHR groups. This alteration was prevented by PARP
inhibition. Our results suggest that PARP-inhibitor treatment has protective effect already in the early stage of hypertensive
myocardial remodeling.
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Introduction
Left ventricular hypertrophy (LVH) represents the heart’s
response to increased biomechanical stress such as arterial
hypertension or valvular heart disease. Cardiac hypertrophy has
traditionally been considered a compensatory mechanism required
to normalize wall tension and to maintain cardiac output.
However, recent clinical studies as well as several animal models
have shown that cardiac hypertrophy is rather a maladaptive
process, ultimately leading to heart failure (HF) and sudden
cardiac death independent of the underlying cause of hypertrophy
[1].
Both physiologic and pathologic stimulation-induced cellular
adaptations of the heart are typically initiated by stress-responsive
signaling pathways, which serve as central transducers of cardiac
hypertrophic growth and/or ventricular dilation. These signaling
pathways include extracellular signal-regulated protein kinases
(ERK), p38 mitogen-activated protein kinases (p38-MAPK), c-Jun
NH2-terminal kinases (JNK) and several protein kinase C (PKC)
isoforms [2]. These pathways and the Akt-1/glycogen synthase
kinase-3b (GSK-3b) signaling cascade have all been demonstrated
to alter their activation state in response to hypertrophic stimuli,
and may therefore contribute to myocardial remodeling [3].
The poly(ADP-ribose) polymerase (PARP) enzyme becomes
activated in response to DNA single-strand breaks that can be
excessive as a response to free radicals and oxidative cell damage.
PARP is an energy-consuming enzyme that transfers ADP-ribose
to nuclear proteins. As a result of this process, the intracellular
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NAD+ and ATP levels decrease remarkably resulting in cell
dysfunction and cell death via the necrotic route. Therefore,
PARP-activation contributes to the pathogenesis of various
cardiovascular diseases including endothelial dysfunction, ische-
mia-reperfusion injury and myocardial infarction, as well as HF.
Several studies reported that endothelial dysfunction associated
with hypertension also depends on PARP activity and can be
prevented by its pharmacological inhibition [4,5].
It has been shown previously that our experimental agent, an
isoquinoline derivative PARP-inhibitor, L-2286 (Fig. 1) had a
beneficial effect against oxidative cell damage, against ischemia-
reperfusion injury and the development of postinfarction or long-
term high blood pressure-induced heart failure. Although the
molecule have a slight scavenger characteristic, its forementioned
effects were mediated mainly by influencing the Akt-1/GSK-3b,
MAPK and PKC signal transduction factors [3,6,7].
Hypertension in spontaneously hypertensive rat (SHR) is similar
to that of human in numerous ways such as the occurence of long-
term, stable LVH followed by a transition to HF [8,9,10]. It makes
SHR a useful tool for studying the development of LVH [9] and
HF, well separated from each other in time. Therefore, our
present study aimed to clarify whether pharmacological PARP-
inhibition has protective effect in an SHR model against the
development of the early stage of hypertensive cardiac remodeling.
Materials and Methods
Ethics Statement
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the U.S. National Insitutes of
Health (NIH Publication No. 85-23, revised 1996), and was
approved by the Animal Research Review Committee of the
University of Pecs, Medical School.
Experimental protocol
Six weeks old male WKY-strain Wistar Kyoto and spontane-
ously hypertensive rats (Charles River Laboratories, Budapest,
Hungary) were used. Animals were kept under standard conditions
throughout the experiment; 12 h light-dark cycle, water and rat
chow provided ad libitum. SHRs were randomly divided into two
groups; SHR-L and SHR-C. SHR-L group was treated with L-
2286 (2-[(2-piperidin-1-ylethyl)thio]quinazolin-4(3H)-one), a wa-
ter-soluble PARP-inhibitor (5 mg/b.w. in kg/day, n = 12), while
SHR-C group received only placebo (n = 11, SHR-C) p. os for 24
weeks [11,12]. WKY rats were used as age-matched controls
(n = 10). Dosage of L-2286 administered in drinking water was
based on preliminary data about the volume of daily consumption
[3,6]. At the beginning and at the end of the 24-week-long period,
echocardiographic measurements were performed. Invasive blood
pressure measurements were carried out on 3 rats of each group at
the end of the study. These rats were anesthetized with ketamine
hydrochloride (Richter Gedeon Ltd., Budapest, Hungary) intra-
peritoneally and a polyethylene catheter (Portex, London, UK)
was inserted into their left femoral artery. Systolic, diastolic and
mean arterial blood pressure was determined by CardioMed
System CM-2005 (Medi-Stim AS, Oslo, Norway). Animals were
euthanized with an overdose of ketamine hydrochloride intraper-
itoneally and heparinized with sodium heparin (100 IU/rat i.p.,
Biochemie GmbH, Kundl, Austria). After the sacrifice, blood was
collected to determine the concentration of plasma brain-derived
natriuretic peptide (BNP), and hearts were removed, the atria and
great vessels were trimmed from the ventricles and weight of the
ventricles was measured, which was then normalized to body mass
(index of cardiac hypertrophy). The lung wet weight-to-dry weight
ratio (an index of pulmonary congestion) was also measured in 7–9
experimental animals [3]. Hearts were freeze-clamped and were
stored at 270uC or fixed in 10% formalin. In order to detect the
extent of fibrotic areas, histologic samples were stained with
Masson’s trichrome. The phosphorylation state of Akt-1/GSK-3b,
MAPK and PKC signaling molecules were monitored by Western
blotting.
Determination of plasma B-type natriuretic peptide
Blood samples were collected into Lavender Vacutainer tubes
containing EDTA and aprotinin (0.6 IU/ml of blood), and were
centrifuged at 1600 g for 15 minutes at 4uC to separate the
plasma. Supernatants were collected and kept at 270uC. BNP-45
were determined by enzyme immunoassay method as the
manufacturer proposed (BNP-45, Rat EIA Kit, Phoenix Pharma-
ceuticals Inc., CA, USA).
Histology
Ventricles fixed in formalin were embedded in paraffin, and
5 mm thick sections were cut from base to apex. Sectiones were
stained with Masson’s trichrome staining to detect the interstitial
fibrosis, and quantified by the NIH ImageJ image processing
program as described previously [3].
Western blot analysis
Fifty milligrams of heart samples were homogenized in ice-cold
50 mM Tris buffer, pH 8.0 containing protease inhibitor cocktail
1:100, and 50 mM sodium vanadate (Sigma-Aldrich Co.,
Budapest, Hungary), and were harvested in 2x concentrated
sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis
sample buffer. Proteins were separated on 10% or 12% SDS-
polyacrylamide gel and transferred to nitrocellulose membranes.
After blocking (2 h with 3% nonfat milk in Tris-buffered saline),
membranes were probed overnight at 4uC with primary antibodies
recognizing the following antigenes: phospho-specific Akt-1/
protein kinase B-a Ser473 (1:1000), Actin (1:10000), phospho-
specific glycogen synthase kinase (GSK)-3b Ser9 (1:1000),
phospho-specific extracellular signal-regulated kinase (ERK 1/2)
Thr202-Tyr204 (1:1000), phospho-specific p38 mitogen-activated
protein kinase (p38-MAPK) Thr180-Gly-Tyr182 (1:1000), phospho-
specific c-Jun N-terminal kinase (JNK) Thr183-Tyr185 (1:1000),
phospho-specific protein kinase C (PKC) (pan) bII Ser660 (1:1000),
phospho-specific protein kinase C a/bII (PKC a/bII) Thr638/641
(1:1000), phospho-specific protein kinase C d (PKC d) Thr505
(1:1000), phospho-specific protein kinase C f/l (PKC f/l)
Thr410/403 (1:1000), phospho-specific protein kinase C e (PKC e)
Ser729 (1:1000), anti-poly(ADP-ribose) (anti-PAR, 1:5000), phos-
pho-Foxo1A (forkhead transcription factor, FKHR Ser256,
1:1000), Heat shock protein 72 (Hsp72, 1:20000), Heat shock
protein 90 (Hsp90, 1:1000). Antibodies were purchased from Cell
Signaling Technology (Beverly, MA, USA) except from actin,
which was bought from Sigma-Aldrich Co, (Budapest, Hungary),
phospho-specific PKC e, which was purchased from Upstate
(London, UK), anti-PAR, which was purchased from Alexis
Figure 1. Chemical structure of L-2286 (2-[(2-Piperidine-1-
ylethyl)thio]quinazolin-4(3H)-one).
doi:10.1371/journal.pone.0102148.g001
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Biotechnology (London, UK), Hsp90, which was bought from
Santa Cruz Biotechnology (Wembley, UK), Hsp72, which was
purchased from StressGene Biomol GmbH (Hamburg, Germany).
Membranes were washed six times for 5 min in Tris-buffered
saline, pH 7.5 containing 0.2% Tween before addition of goat
anti-rabbit horseradish peroxidase-conjugated secondary antibody
(1:3000 dilution, Bio-Rad, Budapest, Hungary). The antibody-
antigen complexes were visualized by means of enhanced
Table 1. Effect of L-2286 treatment on gravimetric parameters and on plasma BNP in SHR.
WKY SHR-C SHR-L
SAP30w, (mmHg) 12967 19269b 18665b
DAP30w, (mmHg) 8965 12768b 12564b
MAP30w, (mmHg) 10367 14965b 14667b
BW6w (g) 71.0161.89 72.0262.36 69.963.21
BW (g) 393614.01 323.8611.27a 321.8666.8a,c
WV (g) 1.1660.17 1.4560.18b 1.2460.24b,c
WV/BW (mg/g) 2.9560.17 4.4860.12b 3.8560.15b,c
Lung wet weight/dry weight 4.8460.92 4.7960.84 4.7760.99
p-BNP (ng/ml) 2.1960.011 2.3360.034 2.3160.031
WKY: normotensive age-matched control rats, n = 7, SHR-C: SHR age-matched control rats, n = 8, SHR-L: SHR treated with L-2286 for 24 weeks, n = 9. SAP, DAP, MAP30w:
systolic, diastolic and mean arterial blood pressure at 30-week-old age (n = 3 from each group). BW6w: body weight of 6-week-old rats, BW: body weight, WV: weights of
ventricles, BNP: plasma b-type natriuretic peptide. Values are means6S.E.M.
a,0.01 (vs. WKY group),
b,0.05 (vs. WKY group),
c,0.05 (vs. SHR-C).
doi:10.1371/journal.pone.0102148.t001
Figure 2. L-2286 treatment decreased the deposition of interstitial collagen. Sections stained with Masson’s trichrome (n = 5). Scale bars
mean 200 mm. Magnifications 10-fold. WKY (A): normotensive age-matched control rats. SHR-C (B): 30 week-old spontaneously hypertensive rats,
SHR-L (C): 30 week-old spontaneously hypertensive rats treated with L-2286 for 24 week. D: Denzitometric evaluation of the sections is shown. *p,
0.01 vs. WKY, 1p,0.05 vs. WKY, $p,0.05 vs. SHR-C.
doi:10.1371/journal.pone.0102148.g002
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chemiluminescence. After scanning, results were quantified by
NIH ImageJ program. Pixel densities of bands were normalized to
that of the loading controls.
Noninvasive evaluation of cardiac functions and
dimensions
At the start of the experiment, all animals were examined by
echocardiography to exclude rats with any heart abnormalities.
Transthoracic two-dimensional echocardiography was performed
under inhalation anesthesia at the beginning of the experiment
and on the day of sacrifice. Rats were lightly anesthetized with a
mixture of 1.5% isoflurane (Forane, Abbott Laboratories,
Hungary) and 98.5% oxygen. The chest of animals was shaved,
acoustic coupling gel was applied and warming pad was used to
maintain normothermia. Rats were imaged in the left lateral
decubitus position. Cardiac dimensions and functions were
measured from short- and long-axis views at the mid-papillary
level by a VEVO 770 high-resolution ultrasound imaging system
(VisualSonics, Toronto, Canada) equipped with a 25 MHz
transducer. LV fractional shortening (FS), ejection fraction (EF),
LV end-diastolic volume (LVEDV), LV end-systolic volume
(LVESV), and the thickness of septum and posterior wall were
determined. FS (%) was calculated by 100x((LVIDd-LVIDs)/
LVIDd) (LVID: LV inside dimension; d: diastolic; s: systolic), EF
(%) was calculated by 100x((LVEDV-LVESV)/LVEDV), relative
wall thickness (RWT) was calculated by (PW thickness +
interventricular septal thickness)/LVIDd.
Statistical analysis
All data are expressed as mean6SEM. First of all the
homogeneity of the groups was tested by F-test (Levene’s test).
There were no significant differences among the groups.
Comparisons among groups were made using one-way ANOVA
(SPSS for Windows 11.0). For post hoc comparison Bonferroni test
was chosen. Values of p,0.05 were considered statistically
significant.
Results
Effect of L-2286 on normotensive WKY rats was also examined,
but the investigated parameters did not differ significantly from the
non-treated WKY animals. Therefore, data of L-2286 treated
WKY rats were not shown to avoid unnecessary redundancies.
Effect of PARP inhibition on gravimetric parameters of
spontaneously hypertensive rats
Body weights did not differ significantly among the three groups
(WKY: 71.0160.11 g, SHR-C: 72.0362.36 g, SHR-L:
Table 2. L-2286 treatment moderately influenced the echocardiographic parameters in 6 weeks old SHRs.
WKY SHR-C SHR-L
EF (%)6w 67.2660.525 68.461.77 68.2361.81
FS6w 38.6364.47 38.0365.52 39.3564.15
LVEDV6w (ml) 147.27613.88 149.56616.78 149.11614.43
LVESV6w (ml) 46.6364.47 48.0365.52 47.3565.45
Septum6w (mm) 1.260.07 1.1860.05 1.1760.12
PW6w (mm) 1.1960.07 1.1660.067 1.1460.04
LV mass6w (uncorrected) 344.14635.49 351.66636.23 354.77633.23
WKY: normotensive age-matched control rats, n = 7, SHR-C: SHR age-matched control rats, n = 8, SHR-L: n = 9, SHR treated with L-2286 for 24 weeks.EF6w: ejection
fraction, FS6w: fractional shortening, LVEDV6w: left ventricular (LV) end-diastolic volume, LVESV6w: LV end-systolic volume, Septum6w: thickness of septum, PW6w:
thickness of posterior wall, LV mass6w: weights of LVs.
doi:10.1371/journal.pone.0102148.t002
Table 3. L-2286 treatment moderately influenced the echocardiographic parameters in 30 weeks old SHRs.
WKY SHR-C SHR-L
EF (%)30w 69.162.4 68.7262.1 69.0163.2
FS30w 39.861.9 39.0461.85 40.5762.66
LVEDV30w (ml) 279.18618.18 335.87610.36a 326.9469.18a
LVESV30w (ml) 85.7768.56 96.85610.36a 99.81611.85a
Septum30w (mm) 1.4360.04 1.9360.04a 1.7960.05a,b
PW30w (mm) 1.5460.08 2.1560.12a 1.8760.03a,b
RWT30w 0.3860.05 0.50460.02a 0.44560.012a,b
LV mass30w (uncorrected) 1002.81659.5 1370.35679.87a 1121.13653.23a,b
LV mass30/BW30 (mg/g) 2.7360.7 4.2360.8a 3.7060.3a,b
WKY: normotensive age-matched control rats, n = 7, SHR-C: SHR age-matched control rats, n = 8, SHR-L: n = 9, SHR treated with L-2286 for 24 weeks.EF30w: ejection
fraction, F30w: fractional shortening, LVEDV30w: left ventricular (LV) end-diastolic volume, LVESV30w: LV end-systolic volume, Septum30w: thickness of septum, PW30w:
thickness of posterior wall, RWT30w: relative wall thickness, LV mass30w: weights of LVs. Values are mean6S.E.M.
ap,0.05 (vs. WKY group),
bp,0.05 (vs. SHR-C group).
doi:10.1371/journal.pone.0102148.t003
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69.9263.21 g, 6-week-old rats) at the beginning of our study.
However, at the end of the 24-week-long treatment period, body
weights of WKY group were significantly higher than those of
SHR-C and SHR-L groups (WKY: 392.7614.01 g, SHR-C:
323.8611.27 g, SHR-L: 321.966.84 g, p,0.01 WKY vs. SHR
groups, 30-week-old rats). The degree of myocardial hypertrophy
was determined by ventricular weight to body weight ratio (WV/
BW, mg/g). This parameter was significantly increased in SHR
groups compared to the WKY group (WV/BW: WKY:
2.9560.17, SHR-C: 4.4860.12, SHR-L: 3.8560.15, p,0.05
WKY vs. SHR groups). Similar results were obtained in case of
weights of ventricles (WV, WKY: 1.1660.17 g, SHR-C:
1.4560.18 g, SHR-L: 1.2460.24 g, p,0.05 WKY vs. SHR
groups). The WV and WV/BW ratios were significantly decreased
by L-2286 treatment (p,0.05 SHR-L vs. SHR-C). The lung wet
weight-to-dry weight ratio was not elevated significantly in SHR-C
and SHR-L compared to WKY groups (Table 1). All these results
indicate the presence of cardiac hypertrophy without congestive
heart failure in the SHR-C group that was ameliorated in the
SHR-L group.
L-2286 treatment did not influence the levels of plasma
BNP and blood pressure
Slightly elevated plasma BNP levels were found both in SHR-C
and SHR-L groups (not significant vs. WKY group). Although
plasma BNP level was a little higher in SHR-C group than in
SHR-L group, this difference was also not statistically significant
(Table 1). In both SHR groups, blood pressure was significantly
elevated compared to the WKY group (p,0.05). L-2286
treatment did not decrease significantly the elevated blood
pressure (Table 1).
L-2286 decreased the interstitial collagen deposition in
the myocardium
Histological analysis revealed slight interstitial collagen deposi-
tion in the WKY group. Chronic high blood pressure caused
significantly higher collagen deposition in SHR-C rats that was
significantly diminished (p,0.05) in the SHR-L group (Fig. 2).
PARP inhibition decreased the left ventricular
hypertrophy in spontaneously hypertensive rats
At the beginning of the study the echocardiographic parameters
of the three groups did not differ significantly from each other
(Table 2). At the age of 30 weeks there was no significant
difference in LV systolic functions (EF and FS) between the WKY
and SHR groups. Heart rate did not differ significantly during the
anesthesia among the groups. LVESV and LVEDV were
increased significantly in SHRs (p,0.05 WKY vs. SHR-C and
SHR-L), and these unfavorable alterations were not reduced by L-
2286 treatment. The thickness of the septum, and the posterior
Figure 3. Effect of L-2286 treatment on Akt-1Ser473/GSK-3bSer9, FKHRSer256 pathway. Representative Western blot analysis of Akt-1Ser473,
GSK-3bSer9, FKHRSer256 phosphorylation and densitometric evaluation is shown (n= 4). Actin was used as loading control. Values are means6S.E.M.
WKY: normotensive age-matched control rats. SHR-C: 30 week-old spontaneously hypertensive rats, SHR-L: 30 week-old spontaneously hypertensive
rats treated with L-2286 for 24 weeks. *p,0.01 vs. WKY, {p,0.01 vs. SHR-C, 1p,0.05 vs. WKY.
doi:10.1371/journal.pone.0102148.g003
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wall and the relative wall thickness were also increased in SHR
groups (indicating the presence of ventricular hypertrophy)
comparing to the WKY group (p,0.05), and these parameters
could be significantly reduced by the administration of L-2286 (p,
0.05 SHR-C vs. SHR-L group) (Table 3).
Effect of L-2286 treatment on poly-ADP-ribosylation as
well as on the phosphorylation state of Akt-1Ser473/GSK-
3bSer9 and FKHRSer256
Akt-1Ser473 was moderately phosphorylated in WKY group. In
SHR-C group, the phosphorylation of Akt-1Ser473 was more
pronounced (p,0.01 vs. WKY). Moreover, in SHR-L rats the L-
2286 treatment caused further elevation in Akt-1Ser473 phosphor-
ylation (p,0.01 vs. WKY and SHR-C groups) (Fig. 3). The same
result was obtained in the case of GSK-3bSer9 phosphorylation
(Fig. 3).
Another target protein of Akt-1Ser473 (besides GSK3bSer9) is
FKHRSer256. Consistently with the result of Akt-1Ser473 phosphor-
ylation, the strongest phosphorylation (therefore inhibition) could
be observed in SHR-L group (p,0.01 vs. SHR-C and WKY). The
lowest phosphorylation and therefore the highest activity of
FKHR was seen in SHR-C group (p,0.05 vs. WKY, Fig. 3).
To detect the effectivity of L-2286, the ADP-ribosylation of the
samples were analysed by Western-blot. The lowest degree of
ADP-ribosylation was present in SHR-L group, and the most
pronounced ADP-ribosylation was seen in SHR-C group (p,0.05
vs. WKY) (Fig. 4).
Effect of L-2286 on the amount of Hsp72 and 90
There was no significant difference among the three groups in
the level of Hsp72. On the other hand, the level of Hsp90 was
elevated in SHR-L group compared to WKY and SHR-C groups
(p,0.01 SHR-L vs. WKY or SHR-C groups), and the lowest
amount of this protein was present in WKY samples (Fig. 4).
Effect of L-2286 administration on MAPKs
Phosphorylation of p38-MAPKThr180-Gly-Tyr182, ERK 1/
2Thr183-Tyr185 and JNK was the lowest in the WKY group
compared to SHR-C and SHR-L groups (p38-MAPKThr180-Gly-
Tyr182: p,0.01 vs. SHR groups, ERK 1/2: p,0.05 vs. SHR
groups, JNK: p,0.05 vs. SHR groups). In the case of p38-
MAPKThr180-Gly-Tyr182, ERK 1/2Thr183-Tyr185 and JNK, their
phosphorylation was elevated in both SHR-C and SHR-L groups,
but there were no significant differences between the two SHR
groups (Fig. 5, JNK: data not shown).
Figure 4. Effect of L-2286 treatment on the level of Hsp72, 90 and poly(ADP-ribos)ylation. Representative Western-blot analysis of Hsp72,
90, anti-PAR and densitometric evaluations are shown (n = 4). Actin was used as loading control. Values are means6S.E.M. WKY: normotensive age-
matched control rats. SHR-C: 30 week-old spontaneously hypertensive rats, SHR-L: 30 week-old spontaneously hypertensive rats treated with L-2286
for 24 weeks. *p,0.01 vs. WKY, {p,0.01 v.s SHR-C, 1p,0.05 vs. WKY, $p,0.05 vs. SHR-C.
doi:10.1371/journal.pone.0102148.g004
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Influence of L-2286 treatment on the phosphorylation
state of several PKC isoforms
The overall (pan) phosphorylation of PKC (pan bIISer660) was
low in the WKY group and became significantly higher in SHR-C
and SHR-L groups (p,0.01 WKY vs. SHR groups). Administra-
tion of L-2286 could not affect the phosphorylation state of PKC
pan bII Ser660 in SHR-L group compared to the SHR-C group
(Fig. 6).
The lowest phosphorylation could be observed in the WKY
group in case of PKC a/bIIThr638/641, dThr505, f/lThr410/403 and
eSer729 (p,0.01 vs. SHR groups). As PKC f antibody, we used a
combined antibody (i.e. PKC f/l Thr410/403), which did not
discriminate between PKC f and l; PKC l being structurally
highly homologous to PKC f in the COOH-terminal end of the
molecule [12]. L-2286 treatment decreased significantly the
phosphorylation of PKC a/bII Thr638/641 and f, while it could
increase the phosphorylation of eSer729 (PKC a/bII Thr638/641, f,
eSer729: p,0.01, SHR-L vs. SHR-C) (Fig. 6,7). In the case of PKC
dThr505 there was no significant difference between the SHR
groups (Fig. 7).
Discussion
The major findings of this study are that chronic inhibition of
nuclear PARP enzyme reduces excessive ADP-ribosylation of
nuclear proteins, beneficially influences the intracellular signaling
pathways and thus prevents the development of cardiac hypertro-
phy, which is an early consequence of hypertension. We used the
SHR model that is a relevant animal model of essential
hypertension in humans [13]. Our study began at a very early
age (6-week-old) of SHRs, because at this age the blood pressure of
animals is still normal and the hearts show no signs of remodeling.
However, by the end of the study (30 weeks), marked signs of
hypertensive cardiopathy develop in SHRs.
Previously, we have proved that PARP-inhibition could inhibit
the transition of hypertensive cardiopathy to end-stage heart
failure [6], but there is no data about the role of PAPR-inhibitors
against the development of early consequences of hypertension.
Hypertension is a major risk factor for cardiovascular mortality
and morbidity, and it is associated with left ventricular hypertro-
phy and diastolic dysfunction and later with systolic dysfunction
and it can lead to heart failure. There is a strong correlation
between left ventricular mass and the development of cardiovas-
cular pathogies [14]. The development of long-term hypertension-
induced myocardial remodeling can be explained by different
mechanism in the literature, but generally, oxidative stress and
abnormal signaling are considered as molecular basis of the
disease. Peroxynitrite and other reactive species induce oxidative
DNA damage and consequent activation of the nuclear enzyme
PARP. In related animal models of the disease, pharmacological
inhibition of PARP provides significant therapeutic benefits [15].
Figure 5. Effect of L-2286 on the phosphorylation state of MAPK pathway. Representative Western blot analysis of ERK 1/2Thr183-Tyr185, and
p38-MAPKThr180-Gly-Tyr182 phosphorylation and densitometric evaluation is shown (n= 4). Actin was used as loading control. Values are means6S.E.M.
WKY: normotensive age-matched control rats. SHR-C: 30 week-old spontaneously hypertensive rats, SHR-L: 30 week-old spontaneously hypertensive
rats treated with L-2286 for 24 weeks. 1p,0.05 vs. WKY *p,0.01 vs. WKY.
doi:10.1371/journal.pone.0102148.g005
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PARP inhibition and gravimetric parameters in SHR
Significant LV hypertrophy develops by the age of 3 months in
SHR animals but it is more often studied closer to 6 months of age
[16]. In our SHR rats myocardial hypertrophy developed, as
increased WV/BW ratio could be observed. We could not observe
any obvious signs of HF, because BNP activity and the index of
pulmonary congestion was not elevated compared to the WKY
group.
PARP inhibition and interstitial collagen deposition in
SHR
Chronic hypertension leads to excessive collagen deposition
(fibrosis) as part of the process of cardiovascular remodeling. In
our previous studies, when SHR or postinfarcted animals
exhibited overt heart failure, L-2286 also prevented interstitial
fibrosis and adverse structural remodeling [3,6]. In the present
study, our results suggest that PARP inhibitor treatment can exert
marked antifibrotic effect already in this early stage of hypertensive
heart disease.
PARP inhibition and echocardiographic parameters
In our experiment the systolic LV function was not decreased in
SHR rats during the 24-week-long treatment. It is in accordance
with several other studies [8,9,10] involving different experimental
models of pressure overload-induced hypertrophy. During the
development of hypertension, alterations in LV geometry may also
occur as an adaptation to increased pressure overload. In
hypertensive patients, LV geometry can be classified into four
patterns on the basis of LV mass index and RWT and these
patterns have been shown to be closely related to LV function and
to patients’ prognosis [17,18,19]. In this study, increased RWT
and increased WV/BW were found, which indicates concentric
LV hypertrophy [9]. L-2286 treatment decreased significantly the
signs of left ventricular hypertrophy (wall thickness and RWT)
even though the elevated blood pressure of SHR rats was not
influenced by PARP inhibition.
L-2286 treatment and the activity of Akt-1Ser473/
GSK3bSer9 and FKHRSer256 pathway
Previous works demonstrated that PARP inhibitors can induce
the phosphorylation and activation of Akt-1 in reperfused
myocardium, thus raising the possibility that the protective effect
of PARP inhibition can be mediated through the activation of the
prosurvival phosphatidylinositol-3-kinase (PI3-kinase)/Akt-1 path-
way [20]. Akt-1 is a key molecule in the signaling cascade of
physiological hypertrophy [21]. Recent results demonstrate an
important role of Akt/m-TOR signaling in cardiac angiogenesis,
whose disruption contributes to the transition from hypertrophy to
HF [1]. In our experiment, the phosphorylation of Akt-1Ser473 was
far the lowest in WKY group and the highest in SHR-L group.
Phosphorylation and therefore the inhibition of GSK-3bSer9 and
Foxo1 (FKHR) (downstream targets of Akt-1) [22,23] were also
determined. This showed the same pattern as the phosphorylation
of Akt-1. The similar results were obtained in our studies using
Figure 6. Effect of L-2286 administration on the activity of PKC isoenzymes. Representative Western blot analysis of PKC pan bIISer660 and
PKC a/bIIThr638/641 phosphorylation and densitometric evaluations are shown (n= 4). Values are means6S.E.M. WKY: normotensive age-matched
control rats. SHR-C: 30 week-old spontaneously hypertensive rats, SHR-L: 30 week-old spontaneously hypertensive rats treated with L-2286 for 24
weeks. *p,0.01 vs. WKY, {p,0.01 vs. SHR-C.
doi:10.1371/journal.pone.0102148.g006
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PARP inhibitors [20,24] or by suppressing PARP-1 activation by
siRNA technique [25]. These results may indicate that SHR-C
animals tried to compensate for the adverse effects of chronic
hypertension, but failed to do so. On the other hand, L-2286
treatment further elevated Akt activation that could, at least
partially, account for the beneficial changes in the cardial
remodeling of the SHR-L animals.
L-2286 administration and levels of Hsp 72 and 90
Cellular stress leads to the expression of Hsp’s [26]. They are
known to protect the myocardium from the damaging effects of
ischemia and reperfusion [27]. According to the results of Jiang et
al [27] and Shinohara et al [28] the Hsp’s can preserve the
mitochondrial respiratory function and structure which are
damaged in case of cell death. The flux of pro-apoptotic proteins
can be induced by various stimuli, one of them is the decreased
level of ATP. This can be induced by overactivation of PARP-1,
which consumes too much ATP in certain pathologic conditions
[29]. In case of Hsp90 in our study, the level of it was increased by
long-term L-2286 treatment. Besides the activation of Akt-1Ser473,
this can contribute to the cell survival in L-2286 treated rats. The
level of Hsp72 was not influenced significantly by L-2286
administration in our investigation.
L-2286 administration and MAPKs in young SHR
Previous works demonstrated that PARP inhibitors have a
moderate effect on MAPKs in acute phase of myocardial
infarction and in postinfarction heart failure [3,20]. MAPKs are
ubiquitously expressed and their activation is observed in different
heart diseases, including hypertrophic cardiomyopathy, dilated
cardiomyopathy, and ischemic/reperfusion injury in human and
animal models [30]. In our study, the phosphorylation of p38-
MAPKThr180-Gly-Tyr182, JNK and ERK 1/2Thr183-Tyr185 was
elevated both in SHR-C and SHR-L groups. Our results are
consistent with the results of Kacimi et Gerdes [31] using
spontaneously hypertensive heart failure (SHHF) rats. L-2286
treatment did not influence the phosphorylation of p38-MAPK
and JNK. The role of JNK and p38-MAPK-signaling in cardiac
hypertrophy is not fully clarified [1]. However, both p38-MAPK
and JNK transduction cascades have been implicated in the
regulation of hypertrophic response as well as cardiomyopathy and
HF [32]. JNK activity was not altered by L-2286 treatment in
SHR animals, similarly to Hsp72 level. This result is in accordance
with previous data [28] demonstrating that Hsp72 downregulates
JNK by accelerating its dephosphorylation.
The elevated blood pressure may induced ERK activation [33].
Accordingly, activation of ERK1/2 was the lowest in WKY group,
and was higher in SHR-C. Phosphorylation of ERK1/2 was not
Figure 7. Effect of L-2286 administration of PKC isoenzymes. Representative Western blot analysis of PKC dThr505, eSer729 and f/lThr410/403
phosphorylation and densitometric evaluation is shown (n = 4). Actin was used as loading control. Values are means6S.E.M. WKY: normotensive age-
matched control rats. SHR-C: 30 week-old spontaneously hypertensive rats, SHR-L: 30 week-old spontaneously hypertensive rats treated with L-2286
for 24 weeks. *p,0.01 vs. WKY, {p,0.01 vs. SHR-C.
doi:10.1371/journal.pone.0102148.g007
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elevated by L-2286 administration in this study. The in vivo role of
ERK in cardiac hypertrophy has been demonstrated in several
genetically engineered animal models. Cardiac-specific expression
of constitutively activated MEK1 promotes cardiac hypertrophy
without compromised function or long-term animal survival,
suggesting that activation of ERK activity promotes a compen-
sated form of hypertrophy [30]. All these results suggest that
MAPK activation did not participate significantly in mediating the
adverse cardiac effects of chronic hypertension in our model.
PARP inhibition and PKC pathways in young SHR
PARP inhibitors were found to affect PKC isoenzymes [3,17].
The levels of all PKC isoforms increased in SHR groups compared
to the WKY group in our study. Our results are in agreement with
Koide et al. [34] using Dahl Salt-Sensitive rats in cardiac
hypertrophy stage. Recent studies suggested that PKC is critically
involved in the development of cardiac remodeling and HF. The
data also suggest that individual PKC isoforms have different
effects on cell signaling pathways, variously leading to changes in
cardiac contractility, hypertrophic response and tolerance to
myocardial ischaemia in the heart [34].
Activation of PKC pan bIISer660 and dThr505 were not altered by
L-2286 treatment, while activation of a/bIIThr638/641 and f/l
Thr410/403 were attenuated and activation of eSer729 was augmented
by L-2286. These alterations can mediate – at least partly – the
favourable cardiovascular effects of L-2286, similarly as it was
found in previous works [3,20].
PKC a is the most extensively expressed among the myocardial
PKC isoforms, and it is a key regulator of cardiomyocyte
hypertrophic growth [35,36]. PKC a was sufficient to stimulate
cell hypertrophy [37]. Transgenic mice overexpressing PKC b2
exhibited cardiac hypertrophy and decreased LV performance;
this depressed cardiac function improved after the administration
of a PKC b-selective inhibitor [38]. Previous reports suggest that
PKC a and b and PKC f/l are involved in the development of
cardiac hypertrophy and HF. Additionally, PKC e plays a role in
physiological hypertrophic responses [34,39], has cardioprotective
effect [40] and by interacting with Akt-1 and affecting Bcl-2
promote vascular cytoprotection [41]. Accordingly, in our study,
both the activity of Akt-1Ser473 and PKCeSer729 were elevated by
L-2286 administration.
Conclusions
In our study, we examined the effect of a PARP inhibitor (L-
2286) in SHR at the stage of LV hypertrophy. L-2286 exerted a
beneficial effect on the progression of myocardial hypertrophy
(thickness of PW and septum, RWT) and myocardial fibrosis. In
the background of these changes, we did not observe any blood
pressure lowering effect of PARP-inhibition. According to our
results, PARP-inhibition can exert this antihypertrophic effect due
to the activation of several prosurvival (especially Akt-1/GSK-3b,
FKHR, PKCe and Hsp90) and the inhibition of prohypertrophic
(PKC- a/bII, - f/l) protein kinases (Fig.8).
Figure 8. Summary of pathway alterations due to L-2286 treatment.
doi:10.1371/journal.pone.0102148.g008
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